featured
Efficacy and Safety of Inhaled Colistimethate Sodium in Patients With Bronchiectasis and Pseudomonas aeruginosa Infection
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Respiratory Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months
Lancet Respir Med 2024 Sep 06;[EPub Ahead of Print], CS Haworth, M Shteinberg, K Winthrop, A Barker, F Blasi, K Dimakou, LC Morgan, AE O'Donnell, FC Ringshausen, O Sibila, RM Thomson, KJ Carroll, F Pontenani, P Castellani, JD ChalmersFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.